Abstract
As the enantiomers of 1-phenylethanol are valuable intermediates in several industries, the lipase catalyzed kinetic resolution of (R,S) -1-phenylethanol is a relevant research topic. In this study, the goal was to determine the optimum reaction parameters to produce enantiomerically pure 1-phenylethanol by lipase (Novozyme 435) catalyzed kinetic resolution using response surface methodology (RSM). Reactions were performed with 40–400 mM (R,S)-1-phenylethanol, 120–1200 mM vinyl acetate and 2–22 mg/mL biocatalyst concentrations (BC L ), at 20–60 °C and with a stirring rate of 50–400 rpm for 5–120 min. The samples were analyzed using high performance liquid chromatography (HPLC) with a Chiralcel OB column. Optimum reaction parameters to reach 100% enantiomeric excess for the substrate ( ee s ) were determined as follows: substrate concentration (C s ): 240 mM, BC L : 11 mg/mL, at 42 °C with a reaction time of 75 min. Model validation was performed using these conditions and ee s was calculated as 100%, which indicates the predicted model was efficient and accurate. When compared to the literature, it was observed that the reaction time decreased significantly. This is an important result considering the industrial scale perspective.
Highlights
Enantiopure chiral compounds are crucial intermediates in several industries, such as the pharmaceutical, agricultural, fine chemicals, and food industries [1]
Lipase catalyzed kinetic resolution of (R-S)-1-phenylethanol 40–400 mM of (R,S)-1-phenylethanol dissolved in n-hexane was added to a 25 mL sealed glass bioreactor. 120–1200 mM of vinyl acetate and a 2–22 mg/mL biocatalyst were added to the reaction mixture
The residual was dissolved in methyl tert butyl ether (MTBE) and filtered through a 0.45 mm filter
Summary
Enantiopure chiral compounds are crucial intermediates in several industries, such as the pharmaceutical, agricultural, fine chemicals, and food industries [1]. As seen in the example of thalidomide, in some cases, the effects of a distomer might result in irreparable damage [2]. This unwanted outcome showed the strong association between chirality and biological activity. In this way, enantiopure drug intermediates and seeking chiral replacements dominated the pharmaceutical industry so much that the share of chiral drugs in the pharmaceutical drug industry has been growing continuously ever since, especially over the last two decades [1, 3,4,5,6]. 80% of the drugs developed during this time were chiral molecules [5]
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
